Advertisement

Virologica Sinica

, Volume 33, Issue 3, pp 234–240 | Cite as

Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading

  • Chun Xu
  • Mao Xia
  • Gang Meng
  • Chunyan Li
  • Aiqin Jiang
  • Jiwu Wei
Research Article
  • 109 Downloads

Abstract

Oncolytic measles virus (OMV) is a promising antitumor agent. However, the presence of anti-measles neutralizing antibodies (NAbs) against the hemagglutinin (H) protein of OMV is a major barrier to the therapeutic application of OMV in clinical practice. In order to overcome this challenge, specific types of cells have been used as carriers for OMV. Differential loading strategies appear to result in different therapeutic outcomes; despite this, only few studies have reported practical ex vivo loading strategies required for effective treatment. To this end, we systematically evaluated the antitumor efficacy of OMV using different loading strategies; this involved varying the in vitro loading duration and loading dose of OMV. We found that improved oncolysis of carrier cells was achieved by a prolonged loading duration in the absence of NAbs. However, the enhanced oncolytic effect was abrogated in the presence of NAbs. Further, we found that the expression of H protein on the surface of carrier cells was predominantly determined by the loading duration rather than the loading dose. Finally, we showed that NAbs blocked viral transfer by targeting H protein prior to the occurrence of cell-to-cell interactions. Our results provide comprehensive information on the determinants of an effective loading strategy for carrier cell-based virotherapy; these results may be useful for guiding the application of OMV as an antitumor agent in clinical practice.

Keywords

Oncolytic measles virus (OMV) Cell carriers Loading strategy Tumor 

Notes

Acknowledgements

The authors thank Prof. Dr. Stephen J. Russell for providing modified oncolytic MV strains. This study was supported in part by the National Natural Science Foundation of China (81472820, 81773255, 81071860 and 81602702), Jiangsu Special Program for Clinical Medical Science and Technology (BL2014054), the Natural Science Foundation of Jiangsu Province of China (BK20160126), and the Fundamental Research Funds for the Central Universities (021414380223 and 14380336/1-2). Six talent peaks project in Jiangsu Province to JW.

Author Contributions

JW designed the study; CX, MX, GM and CL performed the experiments; CX and MX analyzed the data. CX and JW wrote the manuscript. JW and AJ finalized the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The protocol of this study was approved by the Research Ethics Committee of the Medical School of Nanjing University. The experiments were carried out in accordance with approved guidelines and regulations. All participants were provided with written informed consent.

References

  1. Anderson BD, Nakamura T, Russell SJ, Peng K-W (2004) High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64:4919–4926CrossRefPubMedGoogle Scholar
  2. Arap W, Pasqualini R (2004) Engineered embryonic endothelial progenitor cells as therapeutic Trojan horses. Cancer Cell 5:406–408CrossRefPubMedGoogle Scholar
  3. Avota E, Koethe S, Schneider-Schaulies S (2013) Membrane dynamics and interactions in measles virus dendritic cell infections. Cell Microbiol 15:161–169CrossRefPubMedGoogle Scholar
  4. de Swart RL, Yuksel S, Osterhaus AD (2005) Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79:11547–11551CrossRefPubMedPubMedCentralGoogle Scholar
  5. Dörig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295–305CrossRefPubMedGoogle Scholar
  6. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ (2010) Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70:875–882CrossRefPubMedPubMedCentralGoogle Scholar
  7. Griffin DE, Pan CH (2009) Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 330:191–212PubMedGoogle Scholar
  8. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ (2007) Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15:114–122CrossRefPubMedGoogle Scholar
  9. Jarmy G, Wei J, Debatin KM, Beltinger C (2007) Apoptosis-inducing cellular vehicles for cancer gene therapy: endothelial and neural progenitors. In: Srivastava R (ed) Apoptosis, cell signaling and human diseases. Humana Press, Totowa, pp 279–302CrossRefGoogle Scholar
  10. Lebo EJ, Kruszon-Moran DM, Marin M, Bellini WJ, Schmid S, Bialek SR, Wallace GS, McLean HQ (2015) Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009–2010. Open Forum Infect Dis 2:ofv006CrossRefPubMedPubMedCentralGoogle Scholar
  11. Liu C, Russell SJ, Peng KW (2010) Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 18:1155–1164CrossRefPubMedPubMedCentralGoogle Scholar
  12. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW (2009) Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 15:7246–7255CrossRefPubMedPubMedCentralGoogle Scholar
  13. Malvoisin E, Wild TF (1993) Measles virus glycoproteins: studies on the structure and interaction of the haemagglutinin and fusion proteins. J Gen Virol 74:2365–2372CrossRefPubMedGoogle Scholar
  14. Msaouel P, Iankov ID, Dispenzieri A, Galanis E (2012) Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol 13:1732–1741CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW (2007) Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 14:324–333CrossRefPubMedGoogle Scholar
  16. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ (2009) Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 84:401–407CrossRefPubMedPubMedCentralGoogle Scholar
  17. Power AT, Bell JC (2007) Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15:660–665CrossRefPubMedGoogle Scholar
  18. Wei J, Wahl J, Nakamura T, Stiller D, Mertens T, Debatin KM, Beltinger C (2007) Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas. Gene Ther 14:1573–1586CrossRefPubMedGoogle Scholar
  19. Wild TF, Malvoisin E, Buckland R (1991) Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 72:439–442CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Jiangsu Key Laboratory of Molecular MedicineMedical School of Nanjing UniversityNanjingChina
  2. 2.Drum Tower HospitalMedical School of Nanjing UniversityNanjingChina
  3. 3.Nanjing University Hightech Institute at SuzhouSuzhouChina

Personalised recommendations